MYO5B and breast cancer: In mouse models of breast cancer and breast cancer bone metastasis, LRP5-overexpressing osteocyte-derived CM markedly reduced tumor burden and osteolytic lesions, whereas genetic knockdown of either LIMA1 or MYO5B abolished these protective effects.